Genomic Tests to Guide Choice of Chemotherapy
Filed in archive Diagnostics, Methodologies and Instrumentation , Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics by ruth on October 23, 2006
's cancerous tumor, based on the tumor's genomic profile.
The new tests have the potential to save lives and reduce patients' exposure to the toxic side effects of chemotherapy, said Anil Potti, M.D., the study's lead investigator and an assistant professor of medicine in the Duke Institute for Genome Sciences & Policy. The tests are designed to help doctors select and initiate treatment with the best drug for a patient's tumor instead of trying various drugs in succession until the right one is found, Potti said.Preliminary tests indicate that the test is about 80% accurate, and clinical trials are planned for next year. The results of the preliminary study has been published in Nature Medicine (doi:10.1038/nm1491). For an overview, see the press release from Duke University Medical Center.
Permalink: Genomic Tests to Guide Choice of Chemotherapy
Tags:
genomics chemotherapy cancer diagnostics tumor genetics biotech genomic+tests
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/40091






